Background
==========

Numerous common genetic variants have been linked to blood pressure, but no underlying mechanism has been elucidated. Population studies have revealed that a genetic variant, rs5068 (A/G), is associated with blood pressure and the risk of hypertension. rs5068 lies in the 3' untranslated region (3'UTR) of *NPPA*, the gene encoding atrial natriuretic peptide (ANP), and presence of the minor G allele is associated with increased circulating ANP levels and reduced blood pressure.

Results
=======

We hypothesized the existence of a microRNA (miR) that targets the *NPPA* 3'UTR and that the binding of the miR to the NPPA 3'UTR would be disrupted in transcripts from the rs5068 minor allele. We identified a microRNA, miR-425, that is predicted to bind the sequence spanning rs5068 for the A, but not the G, allele. miR-425 is expressed in human atria and ventricles. Using luciferase-3'UTR reporter constructs, we observed that miR-425 could silence reporter mRNAs carrying the *NPPA* major allele 3'UTR, but not those carrying the minor allele 3'UTR. Similarly, an anti-miR directed against miR-425 augmented expression of the luciferase-NPPA 3'UTR construct containing the major allele but not the minor allele. miR-425 reduced NPPA mRNA levels and ANP synthesis in human cardiomyocytes derived from induced pluripotent stem cells.

Conclusion
==========

Our studies provide mechanistic insights into how a common genetic variant identified in population genetic studies can regulate ANP levels and blood pressure. miR-425 is a novel regulator of ANP production, raising the possibility that miR-425 antagonists could be used to treat disorders of salt overload, including hypertension and heart failure.
